August 9, 2007 - Urologists and radiation oncologists expect the use of Image Guided Radiation Therapy (IGRT) to become much more widespread within the next few years, leading to more focused treatment that will be delivered in fewer sessions, according to a report released by market research group IMV Limited.

Despite the availability of many effective therapies, trade-offs between patient lifestyle factors and potential complications of treatment have led to controversy among urologists and radiation oncologists regarding the optimal mix of treatments for localized prostate cancer.
The report, Trends in the Prostate Cancer Treatment Market: 2007 and Beyond, which included 122 urologists and 115 radiation oncologists throughout the United States, indicated that urologists anticipate the use of laparoscopic radical prostatectomy will grow significantly in the near future, applying nerve-sparing techniques and using robotic assistance to assist in surgery as their first-line treatment of choice for patients with localized disease.
Other findings from the report include:

- over 90 percent of the urologists and all of the radiation oncologists in the survey have ordered or performed EBRT procedures for their patients with prostate cancer during the past twelve months.
- 78 percent of respondents have ordered or performed LDR brachytherapy seed implants for their patients with prostate cancer during the past twelve months.

For more information: www.imvinfo.com


Related Content

News | Image Guided Radiation Therapy (IGRT)

June 7, 2022 — Two-year results from the Dysphagia-Aspiration Related Structures (DARS) trial, which is funded by Cancer ...

Time June 07, 2022
arrow
News | Image Guided Radiation Therapy (IGRT)

May 19, 2022 — Brainlab announced that clinicians at UZ Brussel are the first to treat patients with the company’s new ...

Time May 19, 2022
arrow
News | Radiation Oncology

August 27, 2021 — For decades, the National Comprehensive Cancer Network (NCCN) recommended forgoing post-lumpectomy ...

Time August 27, 2021
arrow
News | Radiation Therapy

June 10, 2020 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides ...

Time June 10, 2020
arrow
News | Radiation Therapy

April 16, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...

Time April 16, 2020
arrow
News | Image Guided Radiation Therapy (IGRT)

February 11, 2020 — Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive ...

Time February 11, 2020
arrow
News | Radiology Imaging

December 12, 2019 — Philips and the Regional Medical Center (RMC) announced a strategic 5-year partnership agreement ...

Time December 12, 2019
arrow
News | Radiation Therapy

October 22, 2019 — The American Society for Radiation Oncology (ASTRO) and the American College of Radiology (ACR) ...

Time October 22, 2019
arrow
News | Image Guided Radiation Therapy (IGRT)

ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac System at Dana-Farber/Brigham and Women's Cancer Center. The MRIdian provides for the delivery of radiation therapy to targeted tumors while simultaneously providing continuous magnetic resonance imaging (MRI).

Time October 08, 2019
arrow
News | Image Guided Radiation Therapy (IGRT)

At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian announced Ethos therapy, an artificial intelligence (AI)-driven holistic solution designed to increase the capability, flexibility and efficiency of radiotherapy. This new solution is designed to deliver an entire adaptive treatment in a typical 15-minute timeslot, from patient setup through treatment delivery.

Time September 16, 2019
arrow
Subscribe Now